Avantor, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Avantor, Inc. (NYSE: AVTR) is a leading global provider of mission-critical products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries; the company offers a broad portfolio encompassing materials and consumables such as ultra-high purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, process chromatography resins and columns, analytical sample prep kits, education and microbiology kits, and clinical trial kits; equipment and instrumentation including filtration systems, virus inactivation systems, incubators, peristaltic pumps, fluid handling tips, and analytical instruments; and services and specialty procurement such as onsite lab and production services, equipment procurement and sourcing, biopharmaceutical material scale-up and development, procurement and material management, general lab services, technical lab services, production services, downstream optimization, and business process consulting. Operating through two primary segments—Laboratory Solutions and Bioscience Production—Avantor supports applications in monoclonal antibodies, recombinant proteins, gene therapies, vaccines, cell therapies, mRNA vaccines and therapies, fluid handling technologies, buffer management, and small molecule products, with a global footprint spanning over 30 countries across the Americas, Europe, and AMEA regions and access to more than 300,000 customer locations. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company maintains an integrated business model with extensive manufacturing, distribution, and sales centers worldwide. Recent developments include the appointment of Emmanuel Ligner as President and CEO to drive growth and value creation in life sciences; divestiture of its clinical services business to Audax Private Equity for $650 million in 2025, rebranded as Resonant Clinical Solutions, to sharpen focus on lab and production businesses while generating approximately $500 million in after-tax cash proceeds for debt reduction; expansion of centralized service center model with a new Boston-area facility featuring specialized glassware washing and autoclaving; a strategic partnership with p-Chip Corporation announced in October 2025 to develop solutions for secure chain-of-identity, enhanced traceability, and digital process control in pharmaceutical and clinical manufacturing; and a significant capacity expansion at its European manufacturing site to quadruple production for biologics and therapies.
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
Why Is Avantor (AVTR) Up 13% Since Last Earnings Report?
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
Avantor Q1 Earnings & Revenues Beat Estimates, Margins Decline
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Avantor, Inc. (AVTR) Q1 2026 Earnings Call Transcript
Avantor, Inc. (AVTR) Q1 Earnings and Revenues Top Estimates
Avantor® Reports First Quarter 2026 Results
Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
Avantor Expands Masterflex Portfolio to Streamline Bioprocessing
Kuehn Law Encourages Investors of Avantor, Inc. to Contact Law Firm
Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
Longleaf Partners Fund Q1 2026 Contributors And Detractors
Avantor Stock Up as New Lab Capabilities Improve Biopharma Support
Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
Comparing First Choice Healthcare Solutions (OTCMKTS:FCHS) and Avantor (NYSE:AVTR)
Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
Avantor® Announces CFO Transition